Skip to main content
  1. Online Event

Early-Career Researchers Webinar Series

Wednesday, Nov. 4 - Thursday, Jan. 21, 2021

Nov. 4, 2020
1:00 – 2:30 p.m. ET

Pilar de la Puente, PhD, Assistant Professor at Sanford Research/University of South Dakota Sanford School of Medicine
Modeling Cancer in 3 Dimensions Using Patient-Derived 3D Cultures 

Lack of efficacy and a low overall success rate of phase I-II clinical trials are the most common failures when it comes to advancing cancer treatment. We have developed a patient-derived 3D culture model to overcome these limitations in breast cancer. Our patient-derived model is capable of supporting the growth and expansion of primary tumors recapitulating the tumor microenvironment constituents and modeling cancer treatment responses to predict clinically effective drug treatment concentrations.

Lubnaa Hossenbaccus, MSc, student at Queen’s University 
Validating the Environmental Exposure Unit as an Experimental Clinical Model for Perennial Allergic Rhinitis

The Environmental Exposure Unit (EEU) is a controlled allergen exposure facility housed in the Kingston Health Sciences Centre in Kingston, Canada. It is one of several controlled allergen challenge facilities (CACFs) around the world used to study allergic rhinitis (AR). AR is an inflammatory disease of the nasal mucosa triggered by allergen exposure. While seasonal allergens such as ragweed have previously been investigated in the EEU, house dust mite, a perennial allergen, has yet to be studied.

View Webinar Recordings

Jan. 21, 2021
10:00 – 11:00 a.m. ET

Emilie Da Silva, PhD, student at National Research Center for the Work Environment and the Technical University of Denmark
The Lung Surfactant Bioassay: Principles, Procedures, and Potential Regulatory Use

The presentation will explore the adequacy and the regulatory readiness of the lung surfactant bioassay for the hazard identification of airborne compounds. The putative outcome pathway AOP 302 leading to immediate adverse lung effects will be outlined. Then, the lung surfactant bioassay will be described and the suitability of the method to predict adverse lung effects in humans and rodents will be presented. Finally, the regulatory readiness of the method will be addressed.